AQEMIA

🔬Aqemia and Sanofi Expand Their Research Collaboration. Two years after we first joined forces in December 2023, Sanofi has nominated a new therapeutic target, expanding the scope of our $140M collaboration and triggering a new milestone payment. This nomination means a lot to us. It reflects the trust built between our teams, and it shows that our physics-based generative AI can deliver on real, hard problems, including first-in-class projects where chemical data is scarce from the start. Across Paris, London, Boston and Frankfurt, our teams and Sanofi's are inventing novel small molecule drugs together, powered by Qemi, our proprietary physics-based generative AI platform. As our CEO and co-founder Maximilien Levesque puts it: "It shows that our physics-based generative AI can deliver on real, hard projects. We are committed to inventing innovative drugs in close alliance with Sanofi's experts." We look forward to what's next. 👇 Full Press Release Link in the comments below. 👇 #DrugDiscovery #GenerativeAI #AIforDrugDiscovery #Pharma #Deeptech

"What matters isn't finding what others have already found, faster. It's finding solutions where no one else has." AI in healthcare is usually sold as an accelerator. Our co-founder Maximilien Levesque sees it differently. Our bet at Aqemia: not to run faster than other labs, but to go where the gaps are, diseases with no existing solution. Pancreatic cancer, ovarian cancer, glioblastoma. How? By combining physics and AI. As Maximilien puts it: it's like having a physics professor teach an AI what makes a molecule a good drug candidate. And here's what sets us apart: not our infrastructure, but the molecules we find, far from the ones that already exist. No massive GPU clusters, no giant data centers. Just our mathematics: frugal, and built to compete at the highest level. Maximilien sat down with the "40 nuances de Next" podcast at VivaTech to talk about all of it. Full interview by FeuilleBlanche in the comments. 👇 #deeptech #AI #DrugDiscovery #oncology #Next40

There is something especially meaningful about seeing your alma mater tell your story. AQEMIA was born within the scientific ecosystem of Université PSL, where fundamental research in statistical physics and AI laid the foundations for a new approach to drug discovery. Being selected for the La French Tech Next40/120 2026 is a great honor. But being recognized by the university where this journey began makes this milestone even more special. It's also a powerful reminder of what can happen when world-class academic research meets entrepreneurship: ideas developed in the lab can become technologies with the potential to transform industries and improve patients' lives. A big thank you to Université PSL for highlighting our journey, and congratulations to Alice & Bob, another remarkable company to emerge from this outstanding ecosystem. Most importantly, thank you to everyone at AQEMIA whose talent, curiosity, and dedication continue to turn an ambitious scientific vision into reality. We're just getting started. 🚀 📖 Read more: https://lnkd.in/e539z5nr #FrenchTechNext40 #PSL #AQEMIA #DeepTech #AI #DrugDiscovery

🇫🇷🚀 Yesterday, AQEMIA had the privilege of welcoming Anne Le Hénanff, French Minister Delegate for Artificial Intelligence and Digital Affairs, and the La French Tech team to our Paris headquarters for the official announcement of the 2026 French Tech Next40/120 cohort. It was an honor to host this milestone for the French innovation ecosystem and to celebrate the companies that are helping shape the future of technology and entrepreneurship in France. We are grateful to La French Tech for their trust and proud to contribute to the momentum of French innovation. Congratulations to all the companies selected for this year's French Tech Next40 and French Tech 120 cohorts. #FrenchTechNext40 #FrenchTech120 #LaFrenchTech #Innovation #DeepTech #AQEMIA

🚀 A proud and memorable day for AQEMIA. We are honored to announce that AQEMIA has been selected to join the 2026 La French Tech Next40 cohort, a recognition of our ambition to transform drug discovery through the power of AI and physics, and of the remarkable work accomplished by our teams. Today was made even more special as we had the privilege of hosting the official announcement of the 2026 French Tech Next40/120 cohort at our Paris headquarters, welcoming Anne Le Hénanff, French Minister Delegate for Artificial Intelligence and Digital Affairs, and the La French Tech team. Beyond the honor itself, we see both this distinction and the opportunity to host this event as recognition of the extraordinary work that happens across AQEMIA every day. This achievement belongs to our entire team, whose talent, commitment, and ambition continue to push the boundaries of what is possible in drug discovery. Congratulations to all the companies joining this year's Next40 and French Tech 120 cohorts. We are proud to be part of such an exceptional community of innovators building the future from France. #FrenchTechNext40 #FrenchTech120 #LaFrenchTech #DeepTech #AI #DrugDiscovery #AQEMIA

France is emerging as a global powerhouse in biotech, where artificial intelligence meets deep science to redefine how drugs are discovered. This Le Figaro article captures the acceleration of this ecosystem, spotlighting key innovators as Aqemia. At Aqemia, we know one thing: AI powered with data alone can't invent but me-too molecules or assist medicinal chemists in their exploration journey. Our approach goes deeper. By combining AI with unique deep physics, from École normale supérieure and CNRS, we model molecular interactions from first principles, at the atomic level. This enables us to explore uncharted territories: completely new molecules, not me-toos, and targets without data. We are not just part of this movement, we are helping shape it. Aqemia sits at the core of a new generation of biotech companies transforming how innovation happens, in close partnership with leading pharmaceutical players.  🚀 A new paradigm in drug discovery is here, driven by first-principles science, powered by AI, and led by pioneers like Aqemia. 👉 Full article: https://lnkd.in/evePuNB3  We’re hiring! Join us to help build the future of drug discovery: https://aqemia.com/careers #AI #DrugDiscovery #QuantumPhysics #Biotech #Innovation #Healthcare #Aqemia

We are proud to share that our CEO, Maximilien Levesque, has been honored as Personality of the Year at the 2026 Grands Prix Check-up Santé organised by RMC/BFM. A remarkable recognition for an exceptional CEO leading a bold vision in drug discovery. Aqemia’s mission is to build a drug invention company that combines AI and physics to design truly original molecules, using physics to guide AI beyond existing chemical space toward novel therapeutic candidates. This accolade reflects a strong vision and our teams’ commitment to accelerating drug discovery. Many thanks to the jury for this prize, and congratulations to all the other award winners of this 6th edition. We look forward to continuing to push the boundaries of drug discovery with AI. #Aqemia #Healthcare #Innovation #AI #DrugDiscovery

It's a busy start to this week here at AQEMIA. As we continue to grow we are opening a number of positions and have a number open and accepting applicants. Please see below for more details: 𝐍𝐄𝐖 𝐑𝐎𝐋𝐄𝐒 𝐓𝐇𝐈𝐒 𝐖𝐄𝐄𝐊: - Application Research Scientist (Platform) - RBFE/ABFE support in drug discovery programs - Data Scientist (Platform) - Statistics, modelling and analysis 𝐏𝐨𝐫𝐭𝐟𝐨𝐥𝐢𝐨 - Head of Program Lead 𝐏𝐥𝐚𝐭𝐟𝐨𝐫𝐦 - Molecular Generation Team Manager - Principal Research Data Scientist 𝐅𝐢𝐧𝐚𝐧𝐜𝐞 - VP Finance 𝐏𝐞𝐨𝐩𝐥𝐞 - Senior Talent Acquisition 𝐂𝐚𝐧'𝐭 𝐬𝐞𝐞 𝐚 𝐦𝐚𝐭𝐜𝐡 𝐫𝐢𝐠𝐡𝐭 𝐧𝐨𝐰? ⬇️ - Spontaneous application (We have plenty of roles opening soon 🚀) You can explore and apply to all open roles here: https://lnkd.in/eYnF6Ujk

The UK isn’t just a gateway to Europe anymore, it’s a launchpad for global growth In partnership with the Department for Business and Trade, we’ve explored how European companies are scaling faster by building in the UK. From access to capital and talent, to a dense, high-quality ecosystem the UK continues to attract some of Europe’s most ambitious businesses looking to go global. As Maximilien Levesque, CEO & cofounder, AQEMIA puts it, the decision to establish in London comes down to one thing: ecosystem quality. Featuring insights from: Claudia S., VP Operations, n8n Tim Lambert, Regional Lead (UK, IE & Nordics), osapiens and more leaders building across borders If you're a founder, operator or investor thinking about where to scale next, this is worth your time https://lnkd.in/eEXvmwUE

“The decision to establish ourselves in London was primarily driven by the ecosystem density", said Maximilien Levesque. From access to top-tier talent at the intersection of AI and biology to proximity to leading research institutions, the UK plays a key role in our global development. 👉 Full article: https://lnkd.in/eCQjSTrN Thank you Sifted and Lara Bryant.